Endoscopy Of Female Reproductive Organs With Hysterosalpingography — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for endoscopy of female reproductive organs with hysterosalpingography. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
3
Active US patents
57/100
Avg vulnerability
—
Annual revenue covered

Originators in Endoscopy Of Female Reproductive Organs With Hysterosalpingography

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Giskit 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating endoscopy of female reproductive organs with hysterosalpingography. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
30
1
35
1
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Exem Foam Kit
AIR POLYMER-TYPE A
 Giskit 3 57 — 2030-10-15

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9034300 Exem Foam Kit method of use 68 2030-10-15
9259494 Exem Foam Kit method of use 62 2035-05-04
9849199 Exem Foam Kit formulation 42 2036-02-11

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9849199 Exem Foam Kit formulation 42 2036-02-11
9259494 Exem Foam Kit method of use 62 2035-05-04
9034300 Exem Foam Kit method of use 68 2030-10-15

Related